Intravitreal Bevacizumab for Retinopathy of Prematurity
Intravitreal Bevacizumab for Retinopathy of Prematurity
复制标题
DOI：
10.1089/jop.2011.0060
复制
发表时间：
2011-12-01
影响因子：
2.3
通讯作者：
Schlichtenbrede, Frank C.
中科院分区：
文献类型：
--
作者：
Harder, Bjoern C.;von Baltz, Stefan;Schlichtenbrede, Frank C.
背景资料：目的：评价贝伐单抗玻璃体内注射治疗早产儿视网膜病变（retinopathy of premature，ROP）阈值性视网膜病变的疗效。方法：回顾性研究所有在眼底I区或II区出现ROP阈值的婴儿，并连续接受贝伐单抗玻璃体内注射结果：12例（23眼）患儿入选研究。平均出生体重为625 +/- 187 g（平均值+/-标准差;范围：450-810 g），平均胎龄为25.1 +/- 1.4周（范围：24.0-28.7周），干预时的平均年龄为38.1 +/- 3.7孕周（范围：32.1-45.6周），平均随访时间为30.4 ± 25.9周。3例（6眼）儿童眼表现为侵袭性后房型ROP。注射后，所有眼睛在2-6天内显示出正疾病的消退，瞳孔僵硬度降低，任何图尼卡晶状体血管膜消退，并且在2-3周内视网膜新生血管完全消退。在没有一个孩子的第二次玻璃体内注射贝伐单抗performed.Conclusions：一个单一的玻璃体内注射0.375毫克贝伐单抗0.03毫升似乎是潜在的帮助阈值ROP的治疗，避免传统的视网膜激光凝固，如不可逆的视网膜瘢痕的副作用。长期影响和副作用可能会在未来的前瞻性随机试验中进行评估。
Background: To evaluate the therapeutic effect of a single intravitreal injection of bevacizumab for treatment of threshold retinopathy in retinopathy of prematurity (ROP).Methods: The retrospective study consisted of all infants who developed threshold ROP in fundus zone I or zone II and who consecutively received an intravitreal injection of bevacizumab (0.375 mg, 0.03 mL) in local anesthesia.Results: Twelve infants (23 eyes) were included into the study. The mean birth weight was 625 +/- 187 g (mean +/- standard deviation; range: 450-810 g), mean gestational age was 25.1 +/- 1.4 weeks (range: 24.0-28.7 weeks), mean age at the time of intervention was 38.1 +/- 3.7 gestational weeks (range: 32.1-45.6 weeks), and mean follow-up was 30.4 +/- 25.9 weeks. Three children (6 eyes) showed aggressive posterior ROP. After the injection, all eyes showed a regression of plus disease within 2-6 days, a decrease in pupillary rigidity, a resolution of any tunica vasculosa lentis, and a complete regression of the retinal neovascularization within 2-3 weeks. In none of the children a second intravitreal injection of bevacizumab was performed.Conclusions: A single intravitreal bevacizumab injection of 0.375 mg in 0.03 mL appears to be potentially helpful for the therapy of threshold ROP avoiding side effects of conventional retinal laser coagulation such as irreversible retinal scarring. Long-term effects and side effects may be assessed in future prospective randomized trials.